Related by context. All words. (Click for frequent words.) 62 Phase #b/#a clinical 62 R roscovitine CDK cyclin 61 PNP inhibitor 61 histone deacetylase HDAC inhibitor 61 refractory chronic lymphocytic 61 generation purine nucleoside 61 MT# MEDI 61 dependent kinase inhibitor 60 targeting CD# 60 essential thrombocythemia ET 60 Vascular Disrupting Agent 60 human antibody neutralizing 60 Files IND 60 ABL inhibitor 59 dasatinib Sprycel ® 59 Geron telomerase technology 59 IAP inhibitor 59 non nucleoside inhibitor 59 N acetylgalactosamine 6 59 cutaneous T 59 VEGFR2 inhibitor 59 mGluR5 negative 58 Voreloxin 58 Bruton tyrosine kinase 58 MET VEGFR2 58 BiTE ® 58 Seliciclib CYC# 58 Personalized Immunotherapy 58 class anticancer quinolone 58 Hsp# Inhibitor 58 radiation sensitizer 58 allosteric modulator NAM 58 targeted radiotherapeutic 58 Initiate Phase 58 BiTE R 58 Palifosfamide 58 Liposomal 58 sodium glucose cotransporter 58 vapreotide acetate 58 Thiarabine 58 lintuzumab SGN 58 metastatic castrate resistant 58 apoptosis proteins 58 panitumumab Vectibix R 58 Cloretazine ® 57 TO AVOID PREGNANCY WHILE 57 TRACON Pharmaceuticals Inc. 57 XL# anticancer compounds 57 Iluvien ® 57 Advanced Renal Cell 57 Phase IIb Trial 57 Acute Myeloid Leukemia AML 57 candidate AQ4N 57 accumulate preferentially 57 mitogen activated ERK kinase 57 orally administered inhibitor 57 sunitinib Sutent ® 57 Wafer polifeprosan 57 Clevudine 57 tumor vascular disrupting 57 Panzem NCD 57 TELINTRA R 57 oral proteasome inhibitor 57 IgG1 monoclonal antibody 57 TRC# 57 Histone Deacetylase 57 Pharmacokinetics PK 57 Cyclooxygenase Inhibiting Nitric Oxide 57 immunotherapeutic agent 57 novel histone deacetylase 57 generation nucleoside analog 57 Alfacell proprietary ribonuclease 56 bevacizumab Avastin R 56 Completes Enrollment 56 Deadlinepix 56 molecular imaging radiopharmaceutical 56 CYT# potent vascular disrupting 56 leading oral taxane 56 developing Bicifadine serotonin 56 ERBITUX cetuximab 56 subcutaneous formulation 56 sarcoma melanoma 56 ADP receptor antagonist 56 FOLOTYN ® 56 Kinase Inhibitor 56 peripherally restricted 56 targeted antifolate 56 TKB# 56 Pivotal Trial 56 Cutaneous T 56 PEGylated anti 56 including piezoresistive electro 56 relapsed refractory multiple myeloma 56 erlotinib Tarceva ® 56 MT#/MEDI-# 56 cetuximab Erbitux R 56 TSX VENTURE COMPANIES 56 cutaneous T cell 56 HDAC Inhibitor 56 ribavirin Copegus ® 56 investigational oral inhibitor 56 PDX pralatrexate 56 Ziel einer europaweiten Verbreitung 56 vascular disrupting agent 56 somatostatin analogue 56 CD3 monoclonal antibody 56 release capsules FENTORA 56 RNAi Therapeutic 56 acid phosphatase PAP 56 Polymerase Inhibitor 56 cytotoxic conjugate 56 opioid induced constipation OIC 56 systemic anaplastic large 56 WRX STi +# mins 56 modified glutathione analog 56 GTC recombinant form 56 cell lymphoma CTCL 56 PROVENGE ® 56 phase IIb clinical 56 6 sulfatase 56 bevacizumab Avastin ® 56 Nucleic Acid Detection Immunoassay 55 ALN HPN 55 ALN TTR 55 JAK2 Inhibitor 55 GLP1 INT TM 55 selective A2A adenosine receptor 55 hyaluronidase enzyme 55 THERAPEUTICS 55 Irinotecan 55 PrevOnco 55 2 methoxyestradiol 55 Refractory Peripheral T 55 alpha folate receptor 55 已经 55 Palifosfamide Zymafos TM 55 Receives Orphan Drug Designation 55 phenylalanine ammonia lyase 55 Combination REOLYSIN R 55 vinorelbine tartrate 55 Quinamed 55 Preclinical Data 55 PDE4 modulators 55 MAY CONTAIN FORWARD LOOKING 55 MKC# MKC# PP 55 pan histone deacetylase 55 Laboratory pH Electrodes 55 tumors GIST 55 Transdrug ® nanoparticle 55 TELCYTA R 55 Nasopharyngeal Electrodes Needle Electrodes 55 MSM# TM chipset 55 Aplidin R 55 JAK1 55 rHuPH# recombinant human 55 NPC 1C 55 drug conjugate 55 Phase 2b Clinical Trial 55 Ofatumumab 55 selective inhibitor 55 Onalta ™ 55 hypoxia activated prodrug 55 TRIOLEX ™ 55 PLEASE READ THE FOLLOWING 55 Bone Augmentation Material 55 Phase III Trial 55 Novel Oral 55 receptor tyrosine kinase inhibitor 55 Presents Preclinical Data 55 BY HEIDI FALLON 55 multi kinase inhibitor 55 Phase Ib study 55 AEL# 55 IL# PE#QQR 55 culpa qui officia deserunt 55 ENABLES 55 以及 55 submitted Biologics License 55 mertansine 55 Drug Candidate 55 Tiuxetan 55 imatinib Gleevec ® 55 Kit CD# positive 55 candidate REP# 55 XOMA 3AB 55 에 을 55 including eniluracil ADH 55 PEGylated Fab fragment 55 Lenalidomide 55 selective androgen receptor modulator 55 TRANSDUR ™ 55 chemosaturation 55 CD# CEA 55 liposomal formulation 55 Trial Evaluating 55 Study Evaluating 55 PARI Pharma GmbH 55 seliciclib CYC# 55 phenyl salicylate methylene blue 55 investigational pan BCR 55 irreversible inhibitor 55 acute peripheral arterial 54 只有 54 metastatic malignant 54 novel VDA molecule 54 Relapsed Refractory 54 Parkinson disease levodopa induced 54 generation Hsp# inhibitor 54 Clinical Trial Results 54 experimental immunotherapeutics antivirals AmpligeGI mucosa resulting 54 cetuximab Erbitux ® 54 novel oral tubulin 54 PROSTASCINT R 54 Randomized Double Blind 54 Clinical Trial Evaluating 54 PEGylated interferon 54 CollaRx 54 Zevalin R Ibritumomab 54 Patient Enrolment 54 H.# Encoder 54 topical gel formulation 54 Janus Kinase 54 Factor Receptor 54 使用 54 volociximab 54 ABLYNX 54 考试 54 vivo fluorescence imaging 54 Augment TM 54 DOXIL R 54 product candidate Lpathomab 54 을 54 EXPANDS ITS 54 polymerase inhibitor 54 TRIAL OF 54 STOCKHOLDERS SHOULD READ 54 GVAX ® 54 ara C 54 dihydrochloride 54 docetaxel Taxotere ® 54 出 54 metastatic carcinoma 54 poly ADP ribose polymerase 54 BiTE antibody 54 SAR# [004] 54 5 FU leucovorin 54 systemic lupus erythematosus rheumatoid 54 mTOR inhibitor 54 ALN TTR# 54 Metastatic Melanoma 54 investigational immunotherapy 54 recurrent NSCLC 54 进行 54 APPLICATION FOR 54 CD4 monoclonal antibody 54 Arch Otolaryngol Head 54 humanized anti 54 Tezampanel 54 diagnostic molecular imaging 54 romidepsin novel 54 agent VDA 54 Phase Ib Clinical Trial 54 personalized dendritic 54 platinum chemotherapeutic 54 EndoBarrier ™ 54 Delaying apoptosis may 54 R sorafenib tablets 54 IN PATIENTS WITH 54 fallopian tube cancers 54 triciribine phosphate monohydrate 54 including thyroiditis RA 54 DURECT proprietary 54 DMAG 54 SANKYO 54 BUSINESS DAYS OF 54 JERARDI@ENQUIRER.COM 54 Syndrome LEMS 54 一些 的 54 答案 54 topically applied SEPA 54 novel emulsion formulation 54 Initiate Clinical Trial 54 PHARMACEUTICALS INC. 54 metastatic colorectal carcinoma 54 TMC# [002] 54 POWER SYSTEMS 54 humanized monoclonal 54 Romidepsin 54 DB# [003] 54 POLYSHIELD ® POLYCLEAR ® 54 Prodrug 54 Soft Tissue Sarcoma 54 BY J. BRADY 54 2 inhibitor CYT# 54 Pegasys ® 54 optic electro magnetic 54 AAG geldanamycin analog 54 CLINICAL TRIAL 54 Omacetaxine 54 Methylnaltrexone 54 BY RYAN ERNST 54 cycle modulating nucleoside 54 vinca alkaloid 54 transthyretin TTR mediated amyloidosis 54 rusalatide acetate 54 -swf file 54 FIBER OPTIC 54 By Sheena Delazio 54 Therapy RecoveryRx TM 54 metastatic castration resistant 54 Aztreonam 54 Sangamo ZFP TF 54 AND PARTNER 54 USB Dongle 54 Nexavar ® 54 AP Photo SEL# 54 系统 54 PROVIDED TO 54 Sangamo ZFP technology 54 assessing T DM1 54 MicroMacro TM Multi 54 但是 54 IIb clinical trial 54 ADDITION OF 54 Begins Dosing 54 small molecule Hedgehog 54 antibody blinatumomab MT#/MEDI-# 54 5 fluorouracil leucovorin 54 Antisense Oligonucleotides 54 TNF Tumor Necrosis Factor 54 Serostim ® 54 年 考研 54 Frozen Shoulder syndrome Adhesive 54 PHARM 54 Epratuzumab 54 MT# [002] 54 Oral Fingolimod 54 injectable polymer 54 Daclizumab 54 benzoic acid hyoscyamine sulfate 54 selective orally bioavailable 54 Initiates Phase II 54 Civacir TM Hepatitis C 54 REVIVE Diabetes 54 Staphylococcus aureus Immune Globulin 54 Pressemitteilung ist allein das 54 TRANSDUR ® 54 By JOSHUA BOWMAN 54 之前 54 PERIPHERAL 53 methionine aminopeptidase 53 DOES NOT CONSTITUTE AN 53 proprietary polysaccharide 53 Files Investigational 53 metaglidasen 53 의 은 53 novel orally inhaled 53 CYC# 53 xenograft model 53 JZP 53 AS# amonafide L malate 53 telomerase inhibitor drug 53 Initiates Enrollment 53 CORP. ANNOUNCES 53 ILUVIEN ® 53 injectable bulking agent 53 virus HCV protease inhibitor 53 chemosensitizer 53 PEG PAL PEGylated recombinant 53 Diffuse Large B 53 3G WCDMA HSPA 53 Epothilone D 53 vaccine GRNVAC1 53 mollit anim id est 53 Randomized Double Blind Placebo 53 Phase Ib clinical trials 53 worsening thrombocytopenia 53 CDK inhibitor 53 XmAb ® 53 Onalta TM 53 small molecule chemotherapeutic 53 UMTS EDGE 53 DNA intercalator 53 sorafenib tablets 53 이다 53 Jari Ketomaa Subaru Impreza 53 randomized controlled Phase 53 CRESTRON 53 tumor xenograft models 53 Gliadel R 53 Grb 2 53 Phase Ib IIa 53 biomodulator 53 acyclovir Lauriad R 53 FROM THE COMPANY 53 intravesical infusion therapy 53 leukemia AML 53 pralatrexate injection folate analogue 53 tiuxetan 53 THIS EMAIL 53 BiTE antibodies targeting 53 PEG IFN 53 BRIM3 53 Orally administered 53 depsipeptide 53 neuropathy sparing 53 口语 53 jms 53 mRNA antagonists 53 IMPLY THAT 53 investigational oral 53 TO SHOWCASE 53 toenail onychomycosis 53 Monoclonal Antibody 53 LI ION 53 Exherin 53 Commences Phase 53 selective kinase inhibitor 53 OF THIS PUBLICATION 53 该 53 PT S# 53 By Jami Marquardt 53 Mantle Cell Lymphoma 53 TRX1 53 CYP#A# CYP#D# 53 FDA APPROVES 53 HOW MUCH WAS 53 HCV RNA polymerase 53 Phase 2b Study 53 Annamycin 53 evaluating picoplatin 53 TLK# 53 这种 的 53 Immune Globulin Human 53 SoftScan ® 53 Anti CD# Antibody 53 Investigational Oral 53 LDK Solar manufactures 53 试题 53 HuMax TF 53 Completes Patient Enrollment 53 vesicular monoamine transporter 53 small molecule tyrosine 53 考研 英语 53 Hedgehog Pathway Inhibitor 53 endoluminal stent graft 53 Surgical Hemostat 53 Xeloda ® 53 novel orally administered 53 antibody MT# 53 HeartMate ® 53 anti CD3 monoclonal 53 Orthop Surg 53 Pralatrexate 53 COMUNICADO DE 53 Pharmacokinetic Study 53 CEO www.squeezetrigger.com +#-#-#-# 53 Nventa proprietary CoVal 53 AFFECT MICROSEMI 'S 53 additionally contraindicated 53 것이다 53 BUPHENYL R 53 cell carcinoma RCC 53 이 을 53 GALNS N acetylgalactosamine 53 Albuferon TM 53 PROTEGE 53 Panzem R 53 Announce License Agreement 53 CONTINUES DOWN 53 selectively binds 53 帮助 53 所有 的 53 Capsulitis 53 Solazed ™ 53 WILL NOT BE REFUNDED 53 Excepteur sint occaecat cupidatat 53 AP PhotoExpress Network 53 PRN FDA Approves 53 Granted Orphan Drug 53 Initiates Phase 53 BiTE 53 small molecule glucokinase 53 relapsed leukemia 53 MGd 53 trastuzumab DM1 T DM1 53 Transdermal System 53 UNTERPREMSTAETTEN Austria Business Wire 53 Recombinant Human 53 initiated Phase Ib 53 THE PROXY SOLICITATION 53 Novel Inhibitor 53 Pivotal Phase III 53 Phase Ib II 53 THE CONSENT SOLICITATION 53 novel synthetic peptide 53 Nasdaq XTLB 53 cytopenias due 53 产品 53 Neck Surg 53 THOSE ANTICIPATED IN 53 DCSW# DCSW# 53 题 53 SECOND ROUND OF 53 Copegus ribavirin 53 FOLFOX6 chemotherapy regimen 53 triggers apoptosis programmed 53 luteinizing hormone releasing 53 Vaccine Adjuvant 53 polysilicon mono 53 CDK cyclin dependent 53 intranasal formulation 53 COMMENCES 53 AND ANNOUNCE 53 CUTTING THE 53 TO SUBMIT 53 selective phosphodiesterase 53 candidate deforolimus 53 BRIM2 53 advanced metastatic renal 53 가 53 methylnaltrexone bromide 53 AND BUYER 'S PREMIUM 53 small molecule thrombopoietin 53 Dose Ranging Study 53 Nasdaq HALO 53 lexidronam injection 53 Phase III Clinical Trial 53 이 의 53 topically administered 53 OR USE OF 53 ID NCT# 53 familial amyloidotic polyneuropathy FAP 53 Xanafide 53 CCNMATTHEWS 53 pmi 53 novel topoisomerase 53 novel nucleoside analog 53 PROXY STATEMENT AND OTHER 53 Electronic Brachytherapy System 53 TRADING LOWER ON #.#X 53 Tesetaxel 53 Medullary Thyroid Cancer 53 Proc Am Soc 53 PDE4 inhibitor 53 overactive bladder AA# 53 CableCARD ™ 53 RON Notch 53 LARGE CAP FUND SHOULD 53 수 53 参加 53 ESTIMATES BASED ON 53 hypereosinophilic syndrome 53 Randomized Double blind 53 MPLAB ICD 53 candidate CRLX# 53 lymphoma CTCL 53 include Phenoptin TM 53 Inc. OTCBB MIVT 53 一种 53 LE SN# 53 SinuNase TM 53 Heart Circ Physiol 53 FEMALES SHOULD BE ADVISED 53 吗 53 으로 53 ANTIBODY 53 AND OPTIONS 53 RELEASES NEW 53 Solzira TM 53 Pivotal Study 53 Brentuximab Vedotin SGN 53 UltiMAb TM 53 Pivotal Phase 53 targets Galectin receptors 53 refractory peripheral T 53 AAV vector carrying 53 asume ninguna responsabilidad sobre 53 NS5A inhibitor 53 Complicated Skin 53 NOTE POSIDUR ™ 53 Ion selective Electrodes 53 OR THE APPLICABLE 53 Bavituximab 53 Hepatitis C Virus HCV 53 polycythemia vera essential thrombocythemia 53 Intravenous Human 53 Cetuximab Erbitux 53 advanced carcinoid 53 翻译 53 precursor messenger RNA 53 Dapagliflozin 52 来 的 52 Ultratrace 52 PRICE GREAT DISCOUNT FREE 52 ALN PCS 52 transthyretin mediated amyloidosis ATTR 52 Ranolazine 52 NU# direct 52 Meets Primary Endpoint 52 THE COMPANY IS NOT 52 candidate AP# 52 Therapeutic Competitors Report 52 MEK Inhibitor 52 Radiation Therapy SIRT 52 T# R# 52 delivers fluocinolone acetonide FA 52 FACTORS THAT CAN MATERIALLY 52 计划 52 Indibulin Zybulin TM 52 大学 英语 52 MVA HPV IL2 52 Phase #/#a trial 52 Patients Treated With 52 MKC# MT 52 peripherally acting 52 5 HT2A inverse 52 R bendamustine hydrochloride 52 ceftazidime 52 peptidic compound 52 Allovectin 7 52 ANY OFFER 52 lenalidomide Revlimid ® 52 hconick@mysuburbanlife.com 52 sodium thiosulfate STS 52 Marketing Approval PMA 52 ID Seq 52 neurosurgery laparoscopic surgery 52 Nucleic Acids Res 52 treat chronic sinusitis 52 CPEALE@ENQUIRER.COM 52 Application MAA 52 alfa 2a 52 selective adhesion molecule 52 Tyrosine Kinase Inhibitor 52 generation PNP inhibitor 52 VELCADE melphalan 52 ocular formulation 52 WIRELESS TELECOMMUNICATION SERVICES INDUSTRY 52 investigational humanized monoclonal antibody 52 GV# [001] 52 Dendritic Cell 52 MEK inhibitor 52 作文 52 参考 52 website www.competitivetech.net 52 PATENT FOR 52 MOV QT 52 cyclobenzaprine hydrochloride extended 52 oral nucleoside analogue 52 coronary stent merged 52 FOR TREATMENT 52 thomson.com 52 XYOTAX TM 52 dave.vanginhoven @ thomson.com dvg 52 WP# [002] 52 tyrosine kinase inhibitor TKI 52 COMPANY 'S CURRENT VIEWS 52 liver resection surgeries 52 DEMONSTRATES 52 induces apoptosis 52 Phase 2a Clinical Trial 52 BY ERIC BRADLEY 52 XmAb TM 52 TRAVIS LONG tlong@newsobserver.com TRAVIS 52 FOR OUR CURRENT 52 Evo IX +# mins 52 iobenguane 52 Opterone R 52 carcinoma HCC 52 selective antagonist 52 metastatic colorectal 52 GENERATED BY 52 potently inhibits 52 PrevOnco ™ 52 miconazole Lauriad ® 52 selective immunoproteasome inhibitor 52 AT# [001] 52 Vicinium TM 52 Nicotine Conjugate Vaccine 52 CCR5 antagonist 52 RU ASIA EUROPE EEU 52 由于 52 就是 52 Payload TAP technology 52 Humanized Anti 52 highly selective inhibitor 52 POTELLIGENT ® 52 Randomized Phase 52 Adjuvant Treatment 52 ENTB 52 AP Photo WCAP# 52 jlw 52 Chronic Hepatitis C 52 diarrhea fatigue asthenia 52 EMG ENG Electrodes Electrosurgical 52 tests miRview TM 52 PRESENTED AT 52 无法 52 fosbretabulin 52 BE MADE PURSUANT TO 52 THE SUNAMERICA FOCUSED ALPHA 52 humanized monoclonal antibody 52 COMPLETES ACQUISITION OF 52 Presents Preclinical 52 MATERIALS REGARDING THE PROPOSED 52 Memory MRAM 52 全球 52 antibody MAb 52 最 52 SWEET SUPER 52 EP# [003] 52 investigational anaplastic lymphoma kinase 52 treating abdominal aortic 52 这 是 52 ® chorionic gonadotropin 52 muco adhesive technology 52 Iluvien TM 52 DECISION WITH RESPECT TO 52 dyskinesia PD LID 52 Chemokine Receptor 52 IS OCCURRING AND 52 relapsed multiple myeloma 52 signal transduction inhibitor 52 Please visit www.ntt.com 52 Phase 2a Study 52 FUNCTIONALITY 52 SMaRT ™ 52 报道 说 52 英语 52 INTRODUCES THE 52 Phase 2b Trial 52 와 52 Relapsed 52 aneurysms AAA 52 GLOBAL STRATEGIC BUSINESS REPORT 52 SECURITY HOLDERS TO READ 52 #/DAY STORAGE FEE 52 HDLink Pro 3D 52 irresponsible nuisances 52 nonlinear algorithm 52 Curaxin CBLC# 52 Dave van Ginhoven 52 Glufosfamide 52 Zemiva ™ 52 nilotinib Tasigna ® 52 대통령 52 Pegylated 52 investigational pharmacologically unique 52 POTENTIAL FOR SIGNIFICANT SNOW 52 其中 52 NOT PACK ITEMS 52 INITIATES 52 ATRA IV 52 Indibulin 52 LEVEL OF EFFICIENCY 52 #nd EORTC NCI 52 omacetaxine mepesuccinate 52 NOT SHIP ANY ITEMS 52 monoclonal antibody IgG1 Mab 52 kinase inhibitor 52 Powerline Communication 52 trial evaluating PRX# 52 PET FROM 52 SOLUTION FOR 52 oral ridaforolimus 52 LHRH antagonist 52 SGLT2 inhibitor 52 small molecule inhibitor 52 huC# DM4 52 Severe Sepsis 52 DIFFICULT TRAVEL 52 uricase 52 lenalidomide Revlimid R 52 Randomized Phase II 52 constitutively activated 52 Antiviral Activity 52 potent antiproliferative 52 Avnet Spartan 52 zur Veröffentlichung bereit 52 四 六级 52 cyclin dependent kinase inhibitor 52 Market Approval PMA 52 sapropterin dihydrochloride Phase 52 SiriusXM programming 52 已 52 activin receptor type 52 Presents Positive 52 Phase IIb Clinical Trial 52 GBP #,#,#.# 52 R lenalidomide 52 arsenic trioxide injection GABITRIL 52 molecule epidermal 52 lymphoid malignancies 52 chronic eosinophilic leukemia 52 NASH Huntington 52 perifosine novel potentially 52 SK TELECOM 52 JOYCE FANG 52 一个 的 52 orally bioavailable 52 unresectable hepatocellular carcinoma HCC 52 PI3K/Akt pathway inhibitor 52 DNA methyltransferase inhibitors 52 OR INVESTMENT DECISION 52 所有 52 ARE NOT INTENDED TO 52 TO READ THE DEFINITIVE 52 OrbusNeich patented endothelial progenitor 52 world safest multivalent 52 TRACON Pharmaceuticals 52 myelodysplastic myeloproliferative diseases 52 Aurora Kinase 52 PROXY STATEMENT AND 52 Evo +# mins 52 TFN.newsdesk @ 52 TERATE ® TERATHANE ® 52 VERBINDLICH IST AUSSCHLIESSLICH DIE 52 HER2 ErbB2 52 BY PAUL MCKIBBEN 52 OLAP ODBO XML 52 nucleoside analog 52 ANNOUNCES FIRST 52 WANG HUI FEN 52 potently inhibit 52 CAN OBTAIN 52 By RENA HAVNER 52 INDUSTRY ASSESSMENTS 52 PADRE 52 SOLARMAX ® STAINMASTER ® 52 investigational antiplatelet agent 52 Convection Enhanced Delivery 52 INVESTMENTS FUND LIMITED CAYMAN 52 ENTER OR TO WIN 52 Treatment Experienced 52 kaj.leers @ thomson.com 52 MAY CAUSE THE 52 topical antifungal product 52 non porcine pancreatic 52 washpost 52 Bosutinib 52 PERFORMA ™ POLARGUARD ® 52 PALIS PGAL ROSV SHOW 52 SOFTWARE FOR 52 Novatel Wireless Merlin 52 gastrointestinal disorders characterized 52 irinotecan doxorubicin oxaliplatin paclitaxel 52 granulocyte macrophage colony stimulating 52 SECURITIES COMMISSION OR OTHER 52 ASSOCIATED WITH TRADING FUTURES 52 #G Coherent 52 Medoxomil 52 MULTIPLE MYELOMA 52 YOURSELF WITH THE FOLLOWING 52 Commence Phase 52 topoisomerase II inhibitor 52 Protease Inhibitor 52 DISMISSAL OF 52 结果 52 miconazole Lauriad R 52 tumor activated prodrug 52 DATA FOR 52 新 的 52 LHRH receptor positive 52 ANTICIPATED DESCRIBED ESTIMATED ASSESSED 52 euro adhoc mit dem 52 INTRODUCES NEW 52 TL# [004] 52 需要 52 ELADUR TM 52 Roferon 52 FORWARD LOOKING STATEMENTS INVOLVE 52 oropharyngeal candidiasis OPC 52 Xyfid TM 52 能够 52 Delipidation 52 AACR symposium 52 CB2 selective receptor agonist 52 OctoPlus licensed 52 Combination Clinical Trial 52 AEG# 52 Electrodes Fetal Scalp Electrodes 52 partner RECEPTORS LLC 52 Custirsen 52 ANNOUNCES PARTNERSHIP WITH 52 rxRNA 52 II Clinical Trial 52 email lovecoach@hotmail.com 52 ® DS methenamine 52 WARRANTY OR 52 CG# [003] 52 VISICOL R 52 Letairis ambrisentan 52 candidates Azedra 52 TO INTEGRATE 52 binds selectively 52 FOLFOX6 52 registrational trial 52 NOT PACK ITEMS PURCHASED 52 CR# CR# 52 THE LAUNCH OF 52 TRO# 52 Celgosivir 52 Drug Eluting Stent System 52 ONCE FILED 52 vitreoretinal disorders 52 highly purified pasteurized 52 Sapacitabine CYC# cell 52 更 的 52 PHASE III 52 TECHNOLOGIES ANNOUNCES 52 到 52 Imatinib mesylate 52 aplastic anemia AA 52 delivered RNAi therapeutic 52 Phase IIa Clinical Trial 52 Chipcon CC# 52 CHEAP ONLINE PHARMACY LOW 52 autologous cellular immunotherapy 52 ONX 52 PN# [003] 52 oral ferric iron 52 Ceflatonin R 52 Melphalan 52 mins #.#secs M 52 ANNOUNCES LAUNCH OF 52 WHAT DO YOU DISLIKE 52 도 52 方面 52 重要 的 52 Glucagon Like Peptide 52 non proident sunt 52 5 HT3 antagonist 52 NASDAQ CYTK announced 52 humanised antibody 52 COMPLETE INVESTMENT PROGRAM 52 方面 的 52 PREMISES ARE IMPROVED WITH 52 IN COMBINATION WITH 52 PURCHASE AND RELATED 52 POL PRO 52 dihydrochloride Phase 3 52 BAG# 52 提供 52 LightTouch TM 52 FBOVESPA 52 Int J Obes Relat 52 THE PROPOSED TRANSACTIONS 52 By JAMAAL ABDUL 52 PHASE II 52 Autor verantwortlich 52 Oral Spray 52 Adjunctive Therapy 52 Therapeutic Vaccine 52 Bendamustine 52 Tom@squeezetrigger.com SqueezeTrigger 52 Elotuzumab 52 R chorionic gonadotropin 52 LEVEL OF ACTIVITY PERFORMANCE 52 ferumoxytol Injection 52 Perifosine KRX 52 METHOD FOR 52 systemically administered 52 는 52 THINGS THAT THE MORTGAGED 52 Biosensor System 52 Pegylated Liposomal Doxorubicin 52 fallopian tube carcinoma 52 antiangiogenesis therapies 52 Pruvel TM 52 aldehyde dehydrogenase ALDH2 deficiency 52 目前 52 SFP + optical 52 REVENGE FOR 52 把 52 Recurrent Glioblastoma 52 DUROS 52 automated radiopharmaceutical distribution 52 prokinetic agent 52 Zemiva TM 52 pseudomorphic high 52 는 의 52 #,# G 3Gs 52 refractory cutaneous T 52 Wpg R2X #B# 52 Prolongs Survival 52 ELECTRONICS INC. 52 MKC# 52 双语 52 refractory metastatic colorectal cancer 52 LIMITED VISIBILITIES AND 52 AN OFFER OF 52 AP Photo BAG# 52 Nektar proprietary 52 Vitro Activity 52 Initiated Phase 52 E se pela 52 catheter occlusion 52 ROADWAYS WILL